NASDAQ:NGM

NGM Biopharmaceuticals Competitors

$25.52

-0.55 (-2.11 %)

(As of 04/16/2021 11:04 AM ET)

Add

Compare

Today's Range

$25.52

Now: $25.52▼

$26.15

50-Day Range

$24.43

MA: $28.11▼

$31.93

52-Week Range

$14.93

Now: $25.52▼

$32.12

Volume331 shs

Average Volume294,161 shs

Market Capitalization$1.96 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.97

NGM Biopharmaceuticals (NASDAQ:NGM) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying NGM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NGM Biopharmaceuticals, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

NGM Biopharmaceuticals vs. Ultragenyx Pharmaceutical Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for NGM Biopharmaceuticals and Ultragenyx Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
Ultragenyx Pharmaceutical	0	6	8	0	2.57

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 53.26%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 20.73%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe NGM Biopharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares NGM Biopharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
Ultragenyx Pharmaceutical	-119.19%	-50.69%	-26.87%

Earnings & Valuation

This table compares NGM Biopharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02
Ultragenyx Pharmaceutical	$103.71 million	70.15	$-402,730,000.00	($7.36)	-14.76

NGM Biopharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Ultragenyx Pharmaceutical on 11 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals vs. Arrowhead Pharmaceuticals Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and NGM Biopharmaceuticals (NASDAQ:NGM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares Arrowhead Pharmaceuticals and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$87.99 million	79.69	$-84,550,000.00	($0.84)	-80.43
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02

NGM Biopharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arrowhead Pharmaceuticals and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%

Risk & Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Arrowhead Pharmaceuticals and NGM Biopharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0	2	10	0	2.83
NGM Biopharmaceuticals	0	0	5	2	3.29

Arrowhead Pharmaceuticals currently has a consensus price target of $85.3077, indicating a potential upside of 26.27%. NGM Biopharmaceuticals has a consensus price target of $39.1111, indicating a potential upside of 53.26%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Summary

NGM Biopharmaceuticals beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals vs. GW Pharmaceuticals Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for NGM Biopharmaceuticals and GW Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
GW Pharmaceuticals	0	10	4	0	2.29

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, indicating a potential upside of 53.26%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe NGM Biopharmaceuticals is more favorable than GW Pharmaceuticals.

Valuation & Earnings

This table compares NGM Biopharmaceuticals and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02
GW Pharmaceuticals	$311.33 million	22.02	$-9,020,000.00	($0.24)	-911.38

GW Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Profitability

This table compares NGM Biopharmaceuticals and GW Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%

Summary

GW Pharmaceuticals beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals vs. Ascendis Pharma A/S Stock

Ascendis Pharma A/S (NASDAQ:ASND) and NGM Biopharmaceuticals (NASDAQ:NGM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Ascendis Pharma A/S and NGM Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$14.98 million	441.02	$-244,180,000.00	($5.25)	-23.41
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02

NGM Biopharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ascendis Pharma A/S and NGM Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0	1	11	0	2.92
NGM Biopharmaceuticals	0	0	5	2	3.29

Ascendis Pharma A/S presently has a consensus target price of $187.6667, indicating a potential upside of 52.69%. NGM Biopharmaceuticals has a consensus target price of $39.1111, indicating a potential upside of 53.26%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Ascendis Pharma A/S.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Profitability

This table compares Ascendis Pharma A/S and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%

Summary

NGM Biopharmaceuticals beats Ascendis Pharma A/S on 12 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals vs. TG Therapeutics Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 13.2% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares NGM Biopharmaceuticals and TG Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
TG Therapeutics	-151,798.69%	-223.96%	-108.08%

Valuation and Earnings

This table compares NGM Biopharmaceuticals and TG Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02
TG Therapeutics	$150,000.00	43,038.06	$-172,870,000.00	($1.83)	-25.09

NGM Biopharmaceuticals has higher revenue and earnings than TG Therapeutics. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for NGM Biopharmaceuticals and TG Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
TG Therapeutics	0	0	5	0	3.00

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, indicating a potential upside of 53.26%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 39.37%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe NGM Biopharmaceuticals is more favorable than TG Therapeutics.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Summary

NGM Biopharmaceuticals beats TG Therapeutics on 11 of the 14 factors compared between the two stocks.

NGM Biopharmaceuticals vs. Ionis Pharmaceuticals Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Profitability

This table compares NGM Biopharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
Ionis Pharmaceuticals	7.82%	6.57%	3.39%

Valuation & Earnings

This table compares NGM Biopharmaceuticals and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.90	$-42,790,000.00	($0.85)	-30.02
Ionis Pharmaceuticals	$1.12 billion	5.15	$303.26 million	$2.08	19.73

Ionis Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for NGM Biopharmaceuticals and Ionis Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
Ionis Pharmaceuticals	2	7	6	0	2.27

NGM Biopharmaceuticals currently has a consensus target price of $39.1111, indicating a potential upside of 53.26%. Ionis Pharmaceuticals has a consensus target price of $57.9091, indicating a potential upside of 41.14%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NGM Biopharmaceuticals is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.